Indian pharma stocks slipped after Donald Trump proposed import tariffs up to 250% on foreign drugs. While SEBI research analysts say India's generics may escape major impact, fears linger over margins and exports. Analysts see Trump's move as a negotiation tactic, not final policy. Stocks like Sun Pharma, Dr Reddy's, and Cipla face near-term pressure but long-term fundamentals remain strong.